Dose estimation of heavy ion beam by microdosimetry. Examination of the method to estimate biological effect from physical measurement of radiation quality

The absorbed dose (AD) of heavy ion (HI) beam (here, carbon beam) in HI therapy (unit, EGy) (Dst) to exert the actual clinical effect is for the irradiation of tumors deep in the body and is thus estimated by AD corrected with the relative biological effectiveness (RBE) of clinical endpoint: i.e., the relation is expressed by the equation RBE=Dst/Drad|same-effect (Drad is AD of the reference X-ray to yield the same effect as the HI used for the intended clinical endpoint). This paper describes the process of the estimation in the title with consideration of depth dependences of AD of HI in accordance to Bragg curve, and of biological AD as determined by colony assay of human salivary gland tumor cells: in NIRS, the desired AD in HI therapy is calculated by multiplying 1.5 to physically measured AD of HI at RBE10% (10% survival of the cells). This factor has been obtained by microdosimetry of Heavy Ion Medical Accelerator in Chiba (HIMAC) ions in NIRS with a small spherical proportional counter (LET-1/2, Far West Technology) of the diameter 1.27 cm having the tissue equivalent plastic wall and chamber filled with 4.4 kPa of propane-based gas to make the tissue-equivalence size 1.0 μm diameter. The measuring principle is based on the microdosimetric kinetic model reported previously. The calculated dose is found to agree with AD in HI therapeutic planning within 10% fluctuation. (R.T.)